Answers are grounded in this paper and cite their sources.
These observations show that most TKIs significantly increase the QTc interval. Particularly in vemurafenib-treated patients, the incidence of patients at risk for arrhythmias is increased. Therefore, especially in case of combined risk factors, ECG monitoring in patients treated with TKIs is strongly recommended.
No takes yet. Share an insight, caveat, or question.
Kloth et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: